Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: Interactions with α1-, 5-HT2- and H1-receptors

Life Sciences

Volumn 78, Issue 20, 2006, Pages 2358-2364

  Schurad, B ^a,b   Horowski, R ^a   Jahnichen S ^b   Gornemann T ^b   Tack, J ^a   Pertz, H H ^b  

^a NeuroBiotec GmbH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

1 adrenoceptors; 5 HT2A receptor; 5 HT2B receptor; Dopamine agonist; Histamine H1 receptor; Proterguride; Transdermal administration; Valvulopathy

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HISTAMINE H1 RECEPTOR; PROTERGURIDE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; ILEUM; IN VITRO STUDY; MALE; NONHUMAN; PARKINSON DISEASE; PULMONARY ARTERY; RAT; SWINE; TAIL ARTERY; VALVULAR HEART DISEASE;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPARKINSON AGENTS; AORTA, THORACIC; ARTERIES; DOPAMINE AGONISTS; ERGOLINES; GUINEA PIGS; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; RATS; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, HISTAMINE H1; RECEPTORS, SEROTONIN; REGIONAL BLOOD FLOW; SPLEEN; SWINE; TAIL; UREA;

ANIMALIA; SUIDAE; SUS SCROFA;

EID: 33645404136     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.09.046     Document Type: Article

References (35)

1. F. Baronti, M.M. Mouradian, K.E. Conant, M. Giuffra, G. Brughitta, and T.N. Chase Partial dopamine agonist therapy of levodopa-induced dyskinesias Neurology 42 1992 1241 1243
2. 2A receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats Neuroscience 117 2003 939 948
3. J. Borbujo, A.L. Garcia-Villalon, J. Valle, B. Gomez, and G. Diequez Postjunctional alpha-1 and alpha-2 adrenoceptors in human skin arteries. An in vitro study Journal of Pharmacology and Experimental Therapeutics 249 1989 284 287
4. T.N. Chase, F. Baronti, G. Fabbrini, I.J. Heuser, J.L. Juncos, and M.M. Mouradian Rationale for continuous dopaminomimetic therapy of Parkinson's disease Neurology 39 Suppl. 2 1989 7 10
5. 1-adrenoceptor subtype mediating contraction of guinea pig spleen European Journal of Pharmacology 260 1994 211 220
6. 2B receptors in the cardiopathy associated with fenfluramine Molecular Pharmacology 57 2000 75 81
7. R. Frederiksson, M.C. Lagerström, L.-G. Lundin, and H.B. Schiöth The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Molecular Pharmacology 63 2003 1256 1272
8. R.F. Furchgott The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory H. Blaschko E. Muscholl Catecholamines, Handbook of Experimental Pharmacology vol. 33 1972 Springer-Verlag Berlin 283 335
9. M.L. Giustizieri, C. Albanesi, J. Fluhr, P. Gisondi, J. Norgauer, and G. Girolomoni H1 histamine receptor mediated inflammatory responses in human keratinocytes Journal of Allergy and Clinical Immunology 114 2004 1176 1182
10. 2B-receptors British Journal of Pharmacology 130 2000 692 698
11. M. Greaves, R. Marks, and I. Robertson Receptors for histamine in human skin blood vessels: a review British Journal of Dermatology 97 1977 225 228
12. Hertzsch, J., 1984. n-Propyl-TDHL (Protergurid), ein neuer hochwirksamer Dopaminagonist, Wirkung und Kinetik am Menschen. Dissertation, Freie Universität Berlin.
13. R. Horowski Pharmacological effects of lisuride and their potential role in further research D.B. Calne R. Horowski R.J. McDonald W. Wuttke Lisuride and Other Dopamine Agonists 1983 Raven Press New York 127 139
14. 2B-receptor activation plays crucial role Movement Disorders 19 2004 1523 1524
15. J. Horvath, R.D. Fross, G. Kleiner-Fisman, R. Lerch, H. Stalder, S. Liaudat, W.J. Raskoff, K.D. Flachsbart, H. Rakowski, J.-C. Pache, P.R. Burkhard, and A.E. Lang Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists Movement Disorders 19 2004 656 662
16. 1B-adrenoceptors are involved in noradrenaline-induced contraction of rat tail artery European Journal of Pharmacology 488 2004 157 167
17. 2B-receptors is not a class effect of the ergolines European Journal of Pharmacology 513 2005 225 228
18. W. Kehr, H. Wachtel, and H.H. Schneider Dopaminergic and antidopaminergic properties of ergolines structurally related to lisuride Acta Pharmaceutica Suecica Suppl. 2 1983 98 110
19. M. Marano, and A.J. Kaumann On the statistics of drug-receptor constants for partial agonists Journal of Pharmacology and Experimental Therapeutics 198 1976 518 525
20. 1-receptor agonists Journal of Medicinal Chemistry 46 2003 5458 5470
21. 1-like receptors Cardiovascular Drugs and Therapy 4 1990 1455 1460
22. 2 receptor subtypes Journal of Pharmacology and Experimental Therapeutics 303 2002 815 822
23. P. Riederer Biochemistry of dopaminergic systems in Parkinson's disease J. van Manen U.K. Rinne Lisuride: A New Dopamine Agonist and Parkinson's Disease 1986 Excerpta Medica Amsterdam 44 53
24. 2B-receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications Circulation 102 2000 2836 2841
25. 1 receptors in isolated arteries of rat and guinea pig Journal of Animal Science 79 2001 2202 2209
26. B. Schurad, J. Tack, and R. Lipp 2004. Transdermal delivery of the dopamine agonist proterguride from drug in adhesive matrix systems Abstract book [P T47], German Pharmaceutical Society, Joint Meeting 2004, Regensburg 2004
27. B. Schurad, J. Tack, and R. Lipp Chemical enhancement of percutaneous absorption of proterguride by N-alkylpyrrolidones European Journal of Pharmaceutical Sciences 23 Suppl. 1 2004 57
28. V. Setola, S.J. Hufeisen, K.J. Grande-Allen, I. Vesely, R.A. Glennon, B. Blough, R.B. Rothman, and B.L. Roth 3,4-Methylendioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro Molecular Pharmacology 63 2003 1223 1229
29. D.V. Simula, W.D. Edwards, H.D. Tazelaar, H.M. Connolly, and H.V. Schaff Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years Mayo Clinic Proceedings 77 2002 139 147
30. F. Stocchi Prevention and treatment of motor fluctuations Parkinsonism and Related Disorders 9 2003 73 81
31. G. Van Camp, A. Flamez, B. Cosyns, J. Goldstein, C. Perdaens, and D. Schoors Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide Neurology 61 2003 859 861
32. G. Van Camp, A. Flamez, B. Cosyns, C. Weytjens, L. Muyldermans, M. van Zandijcke, J. de Suttner, P. Santens, P. Decoodt, C. Moerman, and D. Schoors Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease The Lancet 363 2004 1179 1183
33. H. Wachtel Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to lisuride D.B. Calne R. Horowski R.J. McDonald W. Wuttke Lisuride and Other Dopamine Agonists 1983 Raven Press New York 109 125
34. H. Wachtel, and R. Dorow Dual action of central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride Life Sciences 32 1983 421 432
35. H. Wachtel, R. Dorow, and G. Sauer Novel 8α-aminoergolines with inhibitory and stimulatory effects on prolactin secretion in rats Life Sciences 35 1984 1859 1867